CN111991517A - 一种用于气阴两虚型糖尿病的中药胶囊及其制备方法 - Google Patents
一种用于气阴两虚型糖尿病的中药胶囊及其制备方法 Download PDFInfo
- Publication number
- CN111991517A CN111991517A CN202010906145.3A CN202010906145A CN111991517A CN 111991517 A CN111991517 A CN 111991517A CN 202010906145 A CN202010906145 A CN 202010906145A CN 111991517 A CN111991517 A CN 111991517A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- gypsum
- ginseng
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 68
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 37
- 208000031971 Yin Deficiency Diseases 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 16
- 240000008042 Zea mays Species 0.000 claims abstract description 60
- 229910052602 gypsum Inorganic materials 0.000 claims abstract description 51
- 239000010440 gypsum Substances 0.000 claims abstract description 51
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 48
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 48
- 235000008434 ginseng Nutrition 0.000 claims abstract description 48
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 44
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 44
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 44
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 44
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 44
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 43
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 43
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 43
- 235000011477 liquorice Nutrition 0.000 claims abstract description 43
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 39
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 36
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 36
- 235000005822 corn Nutrition 0.000 claims abstract description 36
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 35
- 241000218989 Trichosanthes Species 0.000 claims abstract description 32
- 241000405414 Rehmannia Species 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 229940107666 astragalus root Drugs 0.000 claims abstract description 19
- 235000001188 Peltandra virginica Nutrition 0.000 claims abstract description 18
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 15
- 241000756042 Polygonatum Species 0.000 claims abstract description 15
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 15
- 239000000341 volatile oil Substances 0.000 claims abstract description 11
- 230000010355 oscillation Effects 0.000 claims abstract description 8
- 241000208340 Araliaceae Species 0.000 claims description 47
- 241000209020 Cornus Species 0.000 claims description 40
- 244000197580 Poria cocos Species 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 235000007244 Zea mays Nutrition 0.000 claims description 24
- 229940089639 cornsilk Drugs 0.000 claims description 24
- 239000001231 zea mays silk Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 18
- 235000006533 astragalus Nutrition 0.000 claims description 17
- 241001633680 Polygonatum odoratum Species 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 12
- 241000045403 Astragalus propinquus Species 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000004233 talus Anatomy 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims description 4
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 4
- 235000004879 dioscorea Nutrition 0.000 claims description 4
- 238000004821 distillation Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008517 radix Trichosanthis Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 48
- 239000000463 material Substances 0.000 abstract description 32
- 230000000857 drug effect Effects 0.000 abstract description 10
- 241000222336 Ganoderma Species 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 240000006766 Cornus mas Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000248825 Peltandra virginica Species 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 description 24
- 230000001603 reducing effect Effects 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 230000006870 function Effects 0.000 description 11
- 230000002708 enhancing effect Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000036737 immune function Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- 230000009084 cardiovascular function Effects 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010017999 Gastrointestinal pain Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000007368 endocrine function Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007102 metabolic function Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002364 anti-haemorrhagic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种用于气阴两虚型糖尿病的中药胶囊,具体涉及中药技术领域,包括以下原料:人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草。本发明可保证降糖宁胶囊的正常功效;在原本配方的基础上添加了苍术、葛根、玉竹和灵芝草四味药材,可有效加强胶囊的益气养阴效果,同时与原本配方中的药材配合使用,使得药物中的有效成分快速发挥药效,对山茱萸和苍术提取挥发油,对玉竹、甘草和灵芝草进行醇提取,药材中有效成分提取更加全面,发挥效果更佳,采用间歇式超声波震荡处理,可有效加强煎煮时药材及有效成分充分接触和混合,药效发挥均匀性更佳。
Description
技术领域
本发明涉及中药技术领域,更具体地说,本发明涉及一种用于气阴两虚型糖尿病的中药胶囊及其制备方法。
背景技术
以中国传统医药理论指导采集、炮制、制剂,说明作用机理,指导临床应用的药物,统称为中药。简而言之,中药就是指在中医理论指导下,用于预防、治疗、诊断疾病并具有康复与保健作用的物质。中药主要来源于天然药及其加工品,包括植物药、动物药、矿物药及部分化学、生物制品类药物。降糖宁胶囊,中成药名,由人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草组成。具有益气,养阴,生津功效,用于治疗气阴两虚型糖尿病。
现有的用于气阴两虚型糖尿病的中药胶囊,药物中的有效成分无法快速发挥效果,药效发挥均匀性不佳。
发明内容
为了克服现有技术的上述缺陷,本发明的实施例提供一种用于气阴两虚型糖尿病的中药胶囊及其制备方法。
为实现上述目的,本发明提供如下技术方案:一种用于气阴两虚型糖尿病的中药胶囊,包括以下重量份的原料:人参1~5份、山药8~16份、生石膏20~40份、知母5~15份、黄芪7~17份、天花粉10~20份、茯苓8~16份、麦冬8~16份、地黄10~20份、地骨皮10~20份、玉米须10~20份、山茱萸4~8份、甘草4~8份、苍术1~5份、葛根1~ 5份、玉竹1~5份、灵芝草1~3份;
进一步的,包括以下重量份的原料:人参1份、山药8份、生石膏20份、知母5份、黄芪7份、天花粉10份、茯苓8份、麦冬8份、地黄10份、地骨皮10份、玉米须10份、山茱萸4份、甘草4份、苍术1份、葛根1份、玉竹1份、灵芝草1份。
进一步的,包括以下重量份的原料:人参5份、山药16份、生石膏40份、知母15 份、黄芪17份、天花粉20份、茯苓16份、麦冬16份、地黄20份、地骨皮20份、玉米须20份、山茱萸8份、甘草8份、苍术5份、葛根5份、玉竹5份、灵芝草3份。
进一步的,包括以下重量份的原料:人参3份、山药12份、生石膏30份、知母10 份、黄芪12份、天花粉15份、茯苓12份、麦冬12份、地黄15份、地骨皮15份、玉米须15份、山茱萸6份、甘草6份、苍术3份、葛根3份、玉竹3份、灵芝草2份。
进一步的,所述人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草均选用无病虫害产品。
进一步的,所述玉米须包括新鲜玉米须和干玉米须,且新鲜玉米须和干玉米须的重量份比为:1∶1。
进一步的,所述苍术、葛根和玉竹的重量份比为:1∶1∶1。
本发明还提供一种用于气阴两虚型糖尿病的中药胶囊的制备方法,具体制备步骤如下:
步骤一:称取上述重量份的人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草;
步骤二:将人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草分别进行粉碎处理,过10~20目筛;
步骤三:取步骤二中的二分之一重量份的山茱萸和苍术,使用蒸馏法提取,过滤,得到挥发油A和药渣B;
步骤四:取步骤二中二分之一重量份的玉竹、甘草和灵芝草使用甲醇进行提取,过滤,然后对甲醇进行蒸发处理,得到醇提取物C和药渣D;
步骤五:将药渣B、药渣D与步骤二中的知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、葛根和四分之三重量份的生石膏以及剩余的山茱萸、甘草、苍术、玉竹和灵芝草加入10倍量水进行煎煮两次,每次2小时,煎煮过程中每14分钟超声波震荡处理1分钟,合并煎液,滤过,得到滤渣E和滤液F;
步骤六:将滤渣E以70%乙醇为溶剂,浸渍24小时后,进行渗漉,收集漉液,回收乙醇,减压浓缩成相对密度为1.10~1.15(90℃),得到渗漉液G;
步骤七:将滤液F和渗漉液G进行混合均匀,然后浓缩至相对密度为1.25(90℃) 的稠膏H;
步骤八:将人参、山药和剩余生石膏进行研磨成粉,先将挥发油A、醇提取物C、人参粉、山药粉和生石膏粉混合均匀之后,再加入到稠膏H中,搅拌混合均匀之后,干燥,粉碎,制粒,装入胶囊,得到用于气阴两虚型糖尿病的中药胶囊。
进一步的,在步骤一之前,先对人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草进行清洁除杂处理。
进一步的,在步骤八中,对人参、山药和生石膏进行研磨处理之后,过200~240目筛。
本发明的技术效果和优点:
1、采用本发明的原料配方所制备出的用于气阴两虚型糖尿病的中药胶囊,可保证降糖宁胶囊的正常功效;苍术,燥湿健脾、祛风散寒、明目,葛根,解肌退热、生津、透疹、升阳止泻,可降低血压、降血糖和解除肠管痉挛等作用,苍术可与生地黄和葛根配合使用,加强补气养阴的效果,降血糖效果更佳,使得药物中的有效成分快速发挥;玉竹,养阴润燥、生津止渴,对肾上腺素、葡萄糖及四氧嘧啶引起的高血糖均有抑制作用,甲醇提取物中水溶部分和正丁醇部分对链脲霉素高血糖有明显抑制作用,还具有增强免疫功能,玉竹可与生地黄配合使用,加强降血糖治疗效果;灵芝草,补气安神、止咳平喘;灵芝草,具有改善心血管功能,表现为强心,降压的作用;具有明显的抗血小板凝聚及抗血栓作用;对呼吸系统,具有祛痰止咳平喘的作用;影响机体代谢和内分泌功能,还有保肝作用;在原本配方的基础上添加了苍术、葛根、玉竹和灵芝草四味药材,可有效加强胶囊的益气养阴效果,同时与原本配方中的药材配合使用,可加强药效,使得药物中的有效成分快速发挥药效,药效发挥更加均匀;
2、本发明在制备用于气阴两虚型糖尿病的中药胶囊的过程中,在步骤二将原料中的各种药材进行粉碎处理,可有效缩小药材的粒径,使得对药材的后续加工处理效果更佳,在步骤三中对山茱萸和苍术进行蒸馏提取挥发油,可在保证药材中有效成分全面提取的同时,将药材中的有效物质快速发挥作用,在步骤四中对玉竹、甘草和灵芝草进行醇提取,可在保证药材中有效成分全面提取的同时,将药材中的有效物质快速发挥作用,在步骤五中,在对药材进行煎煮时采用间歇式超声波震荡处理,可有效加强煎煮时药材及有效成分充分接触和混合,药材中的有效成分混合效果佳,药效发挥均匀性更佳。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1:
本发明提供了一种用于气阴两虚型糖尿病的中药胶囊,包括以下重量份的原料:人参 1份、山药8份、生石膏20份、知母5份、黄芪7份、天花粉10份、茯苓8份、麦冬8 份、地黄10份、地骨皮10份、玉米须10份、山茱萸4份、甘草4份、苍术1份、葛根 1份、玉竹1份、灵芝草1份;
所述人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草均选用无病虫害产品,保证中药材原料的安全性。
所述苍术、葛根和玉竹的重量份比为:1∶1∶1,使得苍术、葛根和玉竹与其他重要的配比更加均匀合理。
所述玉米须包括新鲜玉米须和干玉米须,且新鲜玉米须和干玉米须的重量份比为:1∶ 1,使得玉米须中的有效成分更加完全的进入到药物中,玉米须利用率更高。
本发明还提供一种用于气阴两虚型糖尿病的中药胶囊的制备方法,具体制备步骤如下:
步骤一:称取上述重量份的人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草;
步骤二:将人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草分别进行粉碎处理,过10~20目筛;
步骤三:取步骤二中的二分之一重量份的山茱萸和苍术,使用蒸馏法提取,过滤,得到挥发油A和药渣B;
步骤四:取步骤二中二分之一重量份的玉竹、甘草和灵芝草使用甲醇进行提取,过滤,然后对甲醇进行蒸发处理,得到醇提取物C和药渣D;
步骤五:将药渣B、药渣D与步骤二中的知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、葛根和四分之三重量份的生石膏以及剩余的山茱萸、甘草、苍术、玉竹和灵芝草加入10倍量水进行煎煮两次,每次2小时,煎煮过程中每14分钟超声波震荡处理1分钟,合并煎液,滤过,得到滤渣E和滤液F;
步骤六:将滤渣E以70%乙醇为溶剂,浸渍24小时后,进行渗漉,收集漉液,回收乙醇,减压浓缩成相对密度为1.10~1.15(90℃),得到渗漉液G;
步骤七:将滤液F和渗漉液G进行混合均匀,然后浓缩至相对密度为1.25(90℃) 的稠膏H;
步骤八:将人参、山药和剩余生石膏进行研磨成粉,先将挥发油A、醇提取物C、人参粉、山药粉和生石膏粉混合均匀之后,再加入到稠膏H中,搅拌混合均匀之后,干燥,粉碎,制粒,装入胶囊,得到用于气阴两虚型糖尿病的中药胶囊。
在步骤一之前,先对人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草进行清洁除杂处理。
在步骤八中,对人参、山药和生石膏进行研磨处理之后,过200~240目筛。
实施例2:
与实施例1不同的是,包括以下重量份的原料:人参5份、山药16份、生石膏40份、知母15份、黄芪17份、天花粉20份、茯苓16份、麦冬16份、地黄20份、地骨皮20 份、玉米须20份、山茱萸8份、甘草8份、苍术5份、葛根5份、玉竹5份、灵芝草3 份。
实施例3:
与实施例1-2均不同的是,包括以下重量份的原料:人参3份、山药12份、生石膏 30份、知母10份、黄芪12份、天花粉15份、茯苓12份、麦冬12份、地黄15份、地骨皮15份、玉米须15份、山茱萸6份、甘草6份、苍术3份、葛根3份、玉竹3份、灵芝草2份。
分别取上述实施例1-3所制得的用于气阴两虚型糖尿病的中药胶囊与对照组一降糖宁胶囊、对照组二降糖宁胶囊、对照组三降糖宁胶囊、对照组四降糖宁胶囊和对照组五降糖宁胶囊,对照组一降糖宁胶囊为市面上的普通降糖宁胶囊,对照组二降糖宁胶囊与实施例相比无苍术,对照组三降糖宁胶囊与实施例相比无葛根,对照组四降糖宁胶囊与实施例相比无玉竹,对照组五降糖宁胶囊与实施例相比无灵芝草,分八组分别试用三个实施例中制备的用于气阴两虚型糖尿病的中药胶囊以及五个对照组降糖宁胶囊,每组选择气阴两虚型糖尿病门诊病人30例,其中男15例,女15例(无孕妇),最大年龄65岁,最小年龄 20岁,临床表现为舌质红,少苔,舌干或不干,瘦,少光泽、少神,口干不多饮,便秘,初干后溏,久病不愈,每天服用三次,每次4-6粒,一粒0.4g,进行多项试用并调查,得到以下数据,调查结果如表一所示:
表一:
由表一可知,当用于气阴两虚型糖尿病的中药胶囊的原料配比为:人参3份、山药12份、生石膏30份、知母10份、黄芪12份、天花粉15份、茯苓12份、麦冬12份、地黄15份、地骨皮15份、玉米须15份、山茱萸6份、甘草6份、苍术3份、葛根3份、玉竹3份、灵芝草2份时,益气,养阴,生津效果佳,气阴两虚型糖尿病治疗效果佳,药效发挥更快,药效发挥均匀性更佳,故实施例3中原料配合为本发明的优选方案,配方中的中人参,大补元气、复脉固脱、补脾益肺、生津安神,属补虚药下分类的补气药,可调节中枢神经系统的生理功能,提高机体免疫功能,强心、抗休克,保护和刺激骨髓的造血功能,增加肾上腺皮质激素分泌,调整血糖水平,显著抑制胆固醇的吸收,抗肿瘤,延缓衰老,加强机体的适应性,其提取物能明显促进大鼠器官核酸和蛋白质的合成;山药,补脾养胃、生津益肺、补肾涩精,有促进骨折愈合,降血糖,增强免疫功能,增强消化系统功能等作用;生石膏,具有解热、解渴的作用,有调节免疫系统的作用;知母,清热泻火、生津润燥,有解热、镇痛、消炎和利尿作用;抑制Na+-K+-ATP酶的活性;调节肾上腺素能和胆碱能神经系统;能延缓肝细胞对皮质醇的分解代谢;降低血糖;可抗血小板聚集;抗病原微生物;能延长环己巴比妥引起的睡眠时间;具有利胆、免疫抑制等作用;黄芪,补气固表、利尿、托毒排脓、生肌,对核酸代谢有促进作用;增强造血功能;改善心肌功能,对抗心肌梗死;具有抗氧化、抗病毒、抗癌、改善肾功能和肾组织病理改变等,水煎剂具调节免疫、抗衰老和抗应激作用;天花粉,清热生津、消肿排脓,具有抗艾滋病病毒,降血糖等作用;茯苓,利水渗湿、健脾宁心,可预防胃溃疡,对肝损伤有防治作用;有抗癌作用;且能加快心率,具有利尿、抗菌作用,能提高机体的免疫能力,还有降低血糖、降低胃酸、增强离体心脏心缩等作用;麦冬,养阴生津、润肺清心,有保护心血管系统的作用;增强耐缺氧,延长常压缺氧的存活时间;增强免疫功能;降血糖;延缓衰老;抑制胃肠推进作用,抗菌;地黄,能提高免疫功能,有降血糖、抗肿瘤、抗过敏、保护心血管系统、抗真菌、止血、抗弥漫性血管内凝血和抗炎免疫等作用;地骨皮,用治阴虚潮热、骨蒸盗汗、肺热咳嗽、咯血、衄血、内热消渴,具有解热、降低血压、降血糖、降血脂作用;具有抗微生物作用;玉米须,有利尿、降压、利胆、降血糖、止血等作用;山茱萸,补益肝肾,收涩固脱,可增强免疫系统功能;抗炎;抗失血性休克;降血糖;抑制血小板聚集;改善心功能及血流动力学,抗菌,利尿;甘草,补脾益气、止咳祛痰、缓急定痛、调和药性,甘草有肾上腺皮质激素作用,抗炎、抗溃疡、抗过敏反应,抗癌,抗菌,抗病毒,促进胰液分泌,对离体肠有抑制,调节免疫功能,镇咳祛痰,抗突变,解毒,抗氧化,保护耳前庭功能、利尿,保肝、防止动脉硬化,抗脑缺血,预防糖尿病并发症等作用;苍术,燥湿健脾、祛风散寒、明目,抗胃炎、抗胃溃疡;调节胃肠运动;抗肝损伤;抗缺氧;对烟碱受体有阻断作用,水煎剂可抗实验性胃炎及胃溃疡作用,对胃液量、胃酸度及胃蛋白酶活性均有明显抑制作用,血清性溃疡系因胃黏膜缺血、循环障碍而引起的组织坏死而形成的溃疡,苍术对此有明显效果,还有护肝利胆、抗缺氧等药理作用,同时,苍术可与生地黄和葛根配合使用,加强补气养阴的效果,降血糖效果更佳,使得药物中的有效成分快速发挥;葛根,解肌退热、生津、透疹、升阳止泻,葛根具有p-受体阻断剂作用,是心血管作用的基础;具有明显的解热作用;可收缩或舒张平滑肌;还具有扩张冠状动脉血管和脑血管,增加冠状动脉血流量和脑血流量,降低心肌耗氧量,增加氧供应,降低血压、降血糖和解除肠管痉挛等作用;玉竹,养阴润燥、生津止渴,对肾上腺素、葡萄糖及四氧嘧啶引起的高血糖均有抑制作用,甲醇提取物中水溶部分和正丁醇部分对链脲霉素高血糖有明显抑制作用,还具有增强免疫功能,玉竹可与生地黄配合使用,加强降血糖治疗效果;灵芝草,补气安神、止咳平喘;灵芝草,具有改善心血管功能,表现为强心,降压的作用;具有明显的抗血小板凝聚及抗血栓作用;对呼吸系统,具有祛痰止咳平喘的作用;影响机体代谢和内分泌功能,还有保肝作用;具有抗氧化、延缓衰老的作用,具有明显的抗炎、抗肿瘤作用,对放射损伤有一定防护效应,具免疫加强等作用;对神经系统有镇静作用;还能提高代谢,增强免疫功能;在原本配方的基础上添加了苍术、葛根、玉竹和灵芝草四味药材,可有效加强胶囊的益气养阴效果,同时与原本配方中的药材配合使用,可加强药效,使得药物中的有效成分快速发挥药效,药效发挥更加均匀。
实施例4
在上述优选的技术方案中,本发明提供了一种用于气阴两虚型糖尿病的中药胶囊,包括以下重量份的原料:人参3份、山药12份、生石膏30份、知母10份、黄芪12份、天花粉15份、茯苓12份、麦冬12份、地黄15份、地骨皮15份、玉米须15份、山茱萸6 份、甘草6份、苍术3份、葛根3份、玉竹3份、灵芝草2份。
所述人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草均选用无病虫害产品,保证中药材原料的安全性。
所述苍术、葛根和玉竹的重量份比为:1∶1∶1,使得苍术、葛根和玉竹与其他重要的配比更加均匀合理。
所述玉米须包括新鲜玉米须和干玉米须,且新鲜玉米须和干玉米须的重量份比为:1∶ 1,使得玉米须中的有效成分更加完全的进入到药物中,玉米须利用率更高。
本发明还提供一种用于气阴两虚型糖尿病的中药胶囊的制备方法,具体制备步骤如下:
步骤一:称取上述重量份的人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草;
步骤二:将人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草分别进行粉碎处理,过10~20目筛;
步骤三:取步骤二中的二分之一重量份的山茱萸和苍术,使用蒸馏法提取,过滤,得到挥发油A和药渣B;
步骤四:取步骤二中二分之一重量份的玉竹、甘草和灵芝草使用甲醇进行提取,过滤,然后对甲醇进行蒸发处理,得到醇提取物C和药渣D;
步骤五:将药渣B、药渣D与步骤二中的知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、葛根和四分之三重量份的生石膏以及剩余的山茱萸、甘草、苍术、玉竹和灵芝草加入10倍量水进行煎煮两次,每次2小时,煎煮过程中每14分钟超声波震荡处理1分钟,合并煎液,滤过,得到滤渣E和滤液F;
步骤六:将滤渣E以70%乙醇为溶剂,浸渍24小时后,进行渗漉,收集漉液,回收乙醇,减压浓缩成相对密度为1.10~1.15(90℃),得到渗漉液G;
步骤七:将滤液F和渗漉液G进行混合均匀,然后浓缩至相对密度为1.25(90℃) 的稠膏H;
步骤八:将人参、山药和剩余生石膏进行研磨成粉,先将挥发油A、醇提取物C、人参粉、山药粉和生石膏粉混合均匀之后,再加入到稠膏H中,搅拌混合均匀之后,干燥,粉碎,制粒,装入胶囊,得到用于气阴两虚型糖尿病的中药胶囊。
在步骤一之前,先对人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草进行清洁除杂处理。
在步骤八中,对人参、山药和生石膏进行研磨处理之后,过200~240目筛。
实施例5
与实施例4不同的是,在步骤二中,不对药物进行粉碎处理,直接进行步骤三。
实施例6
与实施例4-5均不同的是,在步骤五中,煎煮时,未进行超声波震荡处理。
分别取上述实施例4-6所制得的用于气阴两虚型糖尿病的中药胶囊与对照组六降糖宁胶囊、对照组七降糖宁胶囊和对照组八降糖宁胶囊进行实验,对照组六降糖宁胶囊与实施例相比无步骤三中的操作,直接进行步骤四;对照组六降糖宁胶囊与实施例相比无步骤四中的操作,直接进行步骤五;对照组八降糖宁胶囊与实施例相比无步骤三和步骤四中的操作;分六组分别试用三个实施例中制备的用于气阴两虚型糖尿病的中药胶囊与以及对照组六降糖宁胶囊、对照组七降糖宁胶囊和对照组八降糖宁胶囊,每组选择气阴两虚型糖尿病门诊病人30例,其中男15例,女15例(无孕妇),最大年龄65岁,最小年龄20岁,临床表现为舌质红,少苔,舌干或不干,瘦,少光泽、少神,口干不多饮,便秘,初干后溏,久病不愈,每天服用三次,每次4-6粒,一粒0.4g,进行多项试用并调查,得到以下数据,调查结果如表二所示:
表二:
由表二可知,在制备降糖宁胶囊的过程中,当实施例四中的制备方法为本发明的优选方案,在步骤二将原料中的各种药材进行粉碎处理,可有效缩小药材的粒径,使得对药材的后续加工处理效果更佳,在步骤三中对山茱萸和苍术进行蒸馏提取挥发油,可在保证药材中有效成分全面提取的同时,将药材中的有效物质快速发挥作用,在步骤四中对玉竹、甘草和灵芝草进行醇提取,可在保证药材中有效成分全面提取的同时,将药材中的有效物质快速发挥作用,在步骤五中,在对药材进行煎煮时采用间歇式超声波震荡处理,可有效加强煎煮时药材及有效成分充分接触和混合,药材中的有效成分混合效果佳,药效发挥均匀性更佳。
需要说明的是,在本文中,诸如第一和第二等之类的关系术语仅仅用来将一个实体或者操作与另一个实体或操作区分开来,而不一定要求或者暗示这些实体或操作之间存在任何这种实际的关系或者顺序。而且,术语“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
最后应说明的是:以上所述仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:包括以下重量份的原料:人参1~5份、山药8~16份、生石膏20~40份、知母5~15份、黄芪7~17份、天花粉10~20份、茯苓8~16份、麦冬8~16份、地黄10~20份、地骨皮10~20份、玉米须10~20份、山茱萸4~8份、甘草4~8份、苍术1~5份、葛根1~5份、玉竹1~5份、灵芝草1~3份。
2.根据权利要求1所述的一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:包括以下重量份的原料:人参1份、山药8份、生石膏20份、知母5份、黄芪7份、天花粉10份、茯苓8份、麦冬8份、地黄10份、地骨皮10份、玉米须10份、山茱萸4份、甘草4份、苍术1份、葛根1份、玉竹1份、灵芝草1份。
3.根据权利要求1所述的一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:包括以下重量份的原料:人参5份、山药16份、生石膏40份、知母15份、黄芪17份、天花粉20份、茯苓16份、麦冬16份、地黄20份、地骨皮20份、玉米须20份、山茱萸8份、甘草8份、苍术5份、葛根5份、玉竹5份、灵芝草3份。
4.根据权利要求1所述的一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:包括以下重量份的原料:人参3份、山药12份、生石膏30份、知母10份、黄芪12份、天花粉15份、茯苓12份、麦冬12份、地黄15份、地骨皮15份、玉米须15份、山茱萸6份、甘草6份、苍术3份、葛根3份、玉竹3份、灵芝草2份。
5.根据权利要求1所述的一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:所述人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草均选用无病虫害产品。
6.根据权利要求1所述的一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:所述玉米须包括新鲜玉米须和干玉米须,且新鲜玉米须和干玉米须的重量份比为:1∶1。
7.根据权利要求1所述的一种用于气阴两虚型糖尿病的中药胶囊,其特征在于:所述苍术、葛根和玉竹的重量份比为:1∶1∶1。
8.根据权利要求1-7任意一项所述的一种用于气阴两虚型糖尿病的中药胶囊的制备方法,其特征在于:具体制备步骤如下:
步骤一:称取上述重量份的人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草;
步骤二:将人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草分别进行粉碎处理,过10~20目筛;
步骤三:取步骤二中的二分之一重量份的山茱萸和苍术,使用蒸馏法提取,过滤,得到挥发油A和药渣B;
步骤四:取步骤二中二分之一重量份的玉竹、甘草和灵芝草使用甲醇进行提取,过滤,然后对甲醇进行蒸发处理,得到醇提取物C和药渣D;
步骤五:将药渣B、药渣D与步骤二中的知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、葛根和四分之三重量份的生石膏以及剩余的山茱萸、甘草、苍术、玉竹和灵芝草加入10倍量水进行煎煮两次,每次2小时,煎煮过程中每14分钟超声波震荡处理1分钟,合并煎液,滤过,得到滤渣E和滤液F;
步骤六:将滤渣E以70%乙醇为溶剂,浸渍24小时后,进行渗漉,收集漉液,回收乙醇,减压浓缩成相对密度为1.10~1.15(90℃),得到渗漉液G;
步骤七:将滤液F和渗漉液G进行混合均匀,然后浓缩至相对密度为1.25(90℃)的稠膏H;
步骤八:将人参、山药和剩余生石膏进行研磨成粉,先将挥发油A、醇提取物C、人参粉、山药粉和生石膏粉混合均匀之后,再加入到稠膏H中,搅拌混合均匀之后,干燥,粉碎,制粒,装入胶囊,得到用于气阴两虚型糖尿病的中药胶囊。
9.根据权利要求8所述的一种用于气阴两虚型糖尿病的中药胶囊的制备方法,其特征在于:在步骤一之前,先对人参、山药、生石膏、知母、黄芪、天花粉、茯苓、麦冬、地黄、地骨皮、玉米须、山茱萸、甘草、苍术、葛根、玉竹和灵芝草进行清洁除杂处理。
10.根据权利要求8所述的一种用于气阴两虚型糖尿病的中药胶囊的制备方法,其特征在于:在步骤八中,对人参、山药和生石膏进行研磨处理之后,过200~240目筛。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010906145.3A CN111991517A (zh) | 2020-09-01 | 2020-09-01 | 一种用于气阴两虚型糖尿病的中药胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010906145.3A CN111991517A (zh) | 2020-09-01 | 2020-09-01 | 一种用于气阴两虚型糖尿病的中药胶囊及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111991517A true CN111991517A (zh) | 2020-11-27 |
Family
ID=73465630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010906145.3A Pending CN111991517A (zh) | 2020-09-01 | 2020-09-01 | 一种用于气阴两虚型糖尿病的中药胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111991517A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022939A (zh) * | 2020-09-01 | 2020-12-04 | 南京同仁堂药业有限责任公司 | 一种用于高血压合并高脂血症的胶囊及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101049440A (zh) * | 2006-04-03 | 2007-10-10 | 北京因科瑞斯生物制品研究所 | 一种用于糖尿病的中药制剂及其制备方法 |
-
2020
- 2020-09-01 CN CN202010906145.3A patent/CN111991517A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101049440A (zh) * | 2006-04-03 | 2007-10-10 | 北京因科瑞斯生物制品研究所 | 一种用于糖尿病的中药制剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
余传隆等: "《中国临床药物大辞典》", 31 August 2018, 中国医药科技出版社 * |
左言富等: "《简明中成药辞典》", 31 October 2002, 上海科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022939A (zh) * | 2020-09-01 | 2020-12-04 | 南京同仁堂药业有限责任公司 | 一种用于高血压合并高脂血症的胶囊及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105920085B (zh) | 一种具有减毒功效的组合物及其制备方法和应用 | |
CN101513437B (zh) | 一种抗疲劳中药组合物及其制备方法 | |
CN101947284B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN108524814A (zh) | 一种用于降低血糖的中药组合物及其制备方法 | |
CN104984210A (zh) | 一种豆蔻良姜解酒蜜及其制备方法 | |
CN111991517A (zh) | 一种用于气阴两虚型糖尿病的中药胶囊及其制备方法 | |
CN101244208A (zh) | 一种治疗抑郁症及焦虑症的中药制剂的制备方法 | |
CN106310023A (zh) | 治疗小细胞肺癌的药物、制备方法及其用途 | |
CN117599125A (zh) | 一种用于治疗骨质疏松症的补钙壮骨中药组合物及制法和应用 | |
CN105902827A (zh) | 提高人体免疫力的中药组合物及其制备方法 | |
CN104825821A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN108782905A (zh) | 桦褐孔菌保健茶及其制作方法和应用 | |
CN107823293A (zh) | 治疗口腔溃疡的瑶医外用散剂及其制备方法 | |
CN104258359A (zh) | 一种用于治疗妊娠反应的中药组合物及其制剂的制备方法 | |
CN114404517A (zh) | 一种用于痛风和降低尿酸的组合物及其用途与制备方法 | |
CN111840411A (zh) | 一种降脂茶的制备方法 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN111888431A (zh) | 一种治疗糖尿病的组合物及其制备方法 | |
CN102430008A (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
CN108967618A (zh) | 桦褐孔菌保健茶及其制作方法和应用 | |
CN116251152B (zh) | 用于生发乌发的中药组合物、中药制剂的制备方法以及应用 | |
CN114588228B (zh) | 一种治疗2型糖尿病的组合物 | |
CN114796417B (zh) | 一种降血糖中药组方及其制备方法 | |
CN102755519A (zh) | 葛根葛花抗口腔溃疡颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201127 |